National Cancer Registry

Definition	A cancer registry is defined as a location, be it an office or institution, where collection, storage, analysis and interpretation of data on cancer patients take place (Jenson et al, 1991).
Objectives	- To measure cancer incidence - To describe cancer by time, place, persons and disease - To provide a national database for further epidemiological research
Case definition	Target cases are: - Incident cases by year of diagnosis - Malignant tumors confirmed by histopathology and/or hematology findings - Cancers of all sites
Sources of data	Data are collected through two main channels: the capture system (passive reporting) and the recapture system (active reporting). 1) The capture system: The capture system is based on physician’s routine reporting of cancer cases. Physician’s complete and send forms: - Directly from their clinic; or - Indirectly through the MOPH Drug Dispensing Center (DDC), where anti-cancer drugs are distributed to eligible patients 2) The recapture system: The recapture system is based on gathering information directly from histopathological and hematological laboratories. Data are collected in various ways, using hard or soft copies, or using database file or individual laboratory results depending on laboratories resources. This process is active since the NCR personnel actually contact the sites to obtain the necessary data. The recapture system validates and complements the capture approach.
Medical coding	The coding of cancer primary sites and cancer morphology is done using International Classification of Diseases for Oncology, third edition (ICD-O-3). The code includes information on the topography (primary site), the histology, the behavior and the grade of the tumor. The structure is C##.# M####/##, where: - C##.# specifies the primary site - M#### specifies the histology - /## specifies the behavior and the grade of the tumor
Reporting form	NCR reporting form

ATC	Name	B/G	Ingredients	Dosage	Form	Price
H02AB09	SOLU CORTEF ACT-O-VIAL	B	Hydrocortisone (sodium succinate) - 250mg	250mg	Injectable lyophilised powder for solution+diluent	421,967 L.L
M01AC02	SORAL	G	Tenoxicam - 20mg/2ml	20mg/2ml	Injectable lyophilised powder for solution+solvent	588,603 L.L
J01DH51	SYNERGIC	G	Imipenem - 500mg, Cilastatin - 500mg		Injectable powder	1,142,266 L.L
L04AC02	SIMULECT	BioTech	Basiliximab - 20mg	20mg	Injectable powder + solvent	131,822,828 L.L
L01XX02	SPECTRILA	BioTech	Asparaginase, recombinant - 10,000IU	10,000IU	Injectable powder for concentrate for solution	21,370,813 L.L
A02BC05	SOLEZOL	G	Esomeprazole - 40mg	40mg	Injectable powder for solution	301,021 L.L
H02AB04	SOLU MEDROL	B	Methylprednisolone sodium succinate - 500mg	500mg	Injectable powder for solution	718,956 L.L
H02AB04	SOLU MEDROL	B	Methylprednisolone sodium succinate - 1g	1g	Injectable powder for solution	1,444,631 L.L
J01DE01	SALAPIME	G	Cefepime - 1g	1g	Injectable powder for solution	618,168 L.L
H02AB04	SOLU MEDROL Act-O-Vial	B	Methylprednisolone sodium succinate - 40mg	40mg	Injectable powder for solution+diluent	313,115 L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 20mg	20mg	Injectable powder for suspension+diluent	L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 30mg	30mg	Injectable powder for suspension+diluent	L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 20mg	20mg	Injectable powder for suspension+diluent	36,504,302 L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 30mg	30mg	Injectable powder for suspension+diluent	54,757,132 L.L
A10BJ02	SAXENDA	BioTech	Liraglutide - 6mg/ml	6mg/ml	Injectable solution	16,747,035 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	205,703 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	221,792 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	268,908 L.L
N02BE01	STOPALGIC	G	Paracetamol - 1g/100ml	1g/100ml	Injectable solution	1,536,012 L.L
N02BE01	SOLUFLEX PARACETAMOL	G	Paracetamol - 1g/100ml	1g/100ml	Injectable solution	211,175 L.L
N02BE01	SUPOFEN	G	Paracetamol - 10mg/ml	10mg/ml	Injectable solution	7,675,286 L.L
N06BX06	SOMAZINA	B	Citicoline (sodium) - 1,000mg/4ml	1,000mg/4ml	Injectable solution	787,492 L.L
L04AB06	SIMPONI	BioTech	Golimumab - 50mg/0.5ml	50mg/0.5ml	Injectable solution	72,719,241 L.L

National Cancer Registry (NCR)